Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Bright Horizons For Dendreon

Bright Horizons For Dendreon

Long Investing Ideas from Seeking Alpha

Tue, 5 Feb 2013

By Giancarlo Nicoli : I'm bullish on Dendreon ( DNDN ), the company behind Provenge, the first ever FDA-approved immunotherapy, which works against prostate cancer ( ( PC ) ) -- but that's hardly news, because I always am bullish on this company (FWIW, the stock doesn't care). Last time I wrote ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.